Evidence method
Sequential · gp.financial.deposits
-2.89% · CORE · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
OPHC · Dec 31, 2025
OptimumBank Holdings, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001493152-26-008143Bank
Evidence method
Yoy · gp.fundamentals.net_income
26.85% · CORE · VALID
Evidence method
Yoy · gp.financial.interest_income
7.92% · CORE · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History60 statesSelf-history eligible
Sep 30, 20214/4 normalizedLevel 3Dec 31, 20214/4 normalizedLevel 3Mar 31, 20225/5 normalizedLevel 3Jun 30, 20225/5 normalizedLevel 3Sep 30, 20225/5 normalizedLevel 3Dec 31, 20225/5 normalizedLevel 3Mar 31, 20235/5 normalizedLevel 3Jun 30, 20235/5 normalizedLevel 3Sep 30, 20235/5 normalizedLevel 3Dec 31, 20234/4 normalizedLevel 3Mar 31, 20244/4 normalizedLevel 3Jun 30, 20243/3 normalizedLevel 3Sep 30, 20243/3 normalizedLevel 3Dec 31, 20243/3 normalizedLevel 3Mar 31, 20253/3 normalizedLevel 3Jun 30, 20253/3 normalizedLevel 3Sep 30, 20253/3 normalizedLevel 3Dec 31, 20253/3 normalizedLevel 3Mar 31, 20263/3 normalizedLevel 3Jun 30, 20263/3 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 9.17%
- Current
- -2.89%
- Delta
- -12.06%
- Previous
- 30.92%
- Current
- 26.85%
- Delta
- -4.07%
- Previous
- 6.44%
- Current
- 7.92%
- Delta
- 1.49%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.